CAS 936623-90-4

Sacubitril-valsartan

Description:

Sacubitril-valsartan is a combination medication primarily used in the treatment of heart failure with reduced ejection fraction. It consists of two active components: sacubitril, a neprilysin inhibitor that enhances the levels of natriuretic peptides, and valsartan, an angiotensin II receptor blocker (ARB) that helps to lower blood pressure and reduce strain on the heart. The mechanism of action involves the dual inhibition of the renin-angiotensin-aldosterone system (RAAS) and the neprilysin pathway, leading to vasodilation, reduced blood volume, and improved cardiac output. Sacubitril-valsartan is typically administered orally and is known for its favorable effects on morbidity and mortality in heart failure patients. Common side effects may include hypotension, hyperkalemia, and renal impairment. The drug is contraindicated in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy. Overall, sacubitril-valsartan represents a significant advancement in heart failure management, offering a novel therapeutic approach to improve patient outcomes.

Formula: (C₂₄H₂₉N₅O₃)·2(C₂₄H₂₉NO₅)·5(H₂O)·6Na

InChI: InChI=1S/C24H29N5O3.C24H29NO5.Na.H2O/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28);4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;1H2/t22-;17-,21+;;/m01../s1

InChI key: InChIKey=IFCNUAFRAJCYKN-DDXUJOENSA-N

SMILES: C([C@H](C[C@H](C(OCC)=O)C)NC(CCC(O)=O)=O)C1=CC=C(C=C1)C2=CC=CC=C2.C(N([C@@H]([C@H](C)C)C(O)=O)C(CCCC)=O)C1=CC=C(C2=C(C=CC=C2)C=3NN=NN3)C=C1.[Na].O

Synonyms:

• <span class="text-smallcaps">L</span>-Valine, N-(1-oxopentyl)-N-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-, compd. with α-ethyl (αR,γS)-γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl[1,1′-biphenyl]-4-pentanoate, sodium salt, hydrate (2:2:6:5)
• Entresto
• L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, compd. with α-ethyl (αR,γS)-γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl[1,1'-biphenyl]-4-pentanoate, sodium salt, hydrate (2:2:6:5)
• Lcz 696
• Neparvis
• Sacubitril mixture with Valsartan
• Sacubitril-valsartan mixt.
• Sacubitril/Valsartan
• Valsartan-Sacubitril sodium
• Valsartan/Sacubitril 3Na-2.5 H2O
• trisodium 3-((1S,3R)-1-(biphenyl-4-ylmethyl)-3-(ethoxycarbonyl)butylcarbamoyl)propionate (S)-3-methyl-2-(pentanoyl-(2-(tetrazol-1-at-5-yl)biphenyl-4'-ylmethyl)amino)butyrate hemipentahydrate
• trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3-methyl-2-(pentanoyl{2''-(tetrazol-5-ylate)biphenyl-4-ylmethyl}amino)butyrate] hemipentahydrate
• LZC696
• (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)hexanamido)-3-methylbutanoic acid
• N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine, compd. with α-ethyl (αR,γS)-γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl[1,1'-biphenyl]-4-pentanoate, sodium salt, hydrate (2)
• LCZ696 interMediate
• LCZ696 Entresto
• [(C24H29N5O3).(C24H29NO5).2.5(H2O).3Na]
• 3-(1-Biphenyl-4-ylMethyl-3-ethoxycarbonyl-1-butylcarbaMoyl)propionate-3'-Methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylMethyl)aMino)butyrate
• Cocrystal of Sacubitril and Valsartan
• Valsartan-sacubitril(LCZ696)
• 4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate

Sodium (S)-2-(N-((2'-(2H-Tetrazol-5-Yl)-[1,1'-Biphenyl]-4-Yl)Methyl)Pentanamido)-3-Methylbutanoic Acid 4-(((2S,4R)-1-([1,1'-Biphenyl]-4-Yl)-5-Ethoxy-4-Methyl-5-Oxopentan-2-Yl)Amino)-4-Oxobutanoic Acid

CAS: 936623-90-4

Sodium (S)-2-(N-((2'-(2H-Tetrazol-5-Yl)-[1,1'-Biphenyl]-4-Yl)Methyl)Pentanamido)-3-Methylbutanoic Acid 4-(((2S,4R)-1-([1,1'-Biphenyl]-4-Yl)-5-Ethoxy-4-Methyl-5-Oxopentan-2-Yl)Amino)-4-Oxobutanoic Acid

Purity: ≥99%

Molecular weight: 1915.99g/mol

Ref: 54-OR1026669

Sacubitril/Valsartan

CAS: 936623-90-4

Sacubitril/Valsartan

Purity: ≥98%

Molecular weight: 957.99g/mol

Ref: 54-BUP16956

Sacubitril/Valsartan

CAS: 936623-90-4

Sacubitril/Valsartan (LCZ696) is an orally bioavailable, dual angiotensin II receptor and neprilysin inhibitor for treatment of hypertension and heart failure.

Formula: C₄₈H₅₅N₆O₈Na₃·5H₂O

Purity: 99.75% - >99.99%

Color and Shape: Solid

Molecular weight: 957.99

Ref: TM-T2318

Valsartan Sacubitril

CAS: 936623-90-4

Formula: C₂₄H₂₈NO₅C₂₄H₂₇N₅O₃Na(H₂₀)

Molecular weight: 410.5 : 433.5 : 3(23.0) : 5/2(18.0)

Ref: ST-EA-CP-V3015

LCZ696

CAS: 936623-90-4

Lcz696 is an ester prodrug of the active compound crizotinib, which is a selective inhibitor of the enzyme tyrosine kinase. Lcz696 has been shown to be effective in combination therapy for the treatment of patients with metastatic non-small cell lung cancer and those who are resistant to first-line chemotherapy. This drug has also been shown to have beneficial effects on cardiac function and blood pressure. Lcz696 inhibits MMP-9 activity and reduces levels of natriuretic peptides, which may be due to its inhibition of Toll-like receptor 4 (TLR4).

Formula: C₂₄H₂₉N₅O₃•C₂₄H₂₉NO₅•(H₂O)₂•Na₃

Purity: Min. 95%

Molecular weight: 1,922.04 g/mol

Ref: 3D-FL137695